Michael Vi/iStock Editorial via Getty Images Johnson & Johnson ( NYSE: JNJ ) reported positive data from a Phase 3b study of its drug Tremfya in the treatment of moderate plaque psoriasis affecting low body surface areas such as the scalp, face, skin folds and genitals. The study showed.
Back to Health Page
